Lenvatinib HCC Results Give Sorafenib Cause To REFLECT?

New comparative data released at ASCO reveal the scope of benefit for Eisai's lenvatinib over close competitor sorafenib in the first-line treatment of unresectable hepatocellular carcinoma. But the Eisai drug may face challenges in carving a position in this setting.